Why These 15 Healthcare Stocks Are Surging in 2025

Page 3 of 14

12. Tiziana Life Sciences Ltd (NASDAQ:TLSA)

Number of Hedge Fund Holders In Q4 2024: N/A

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotechnology company developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases, with a lead focus on its fully human anti-CD3 monoclonal antibody, Foralumab, for conditions such as secondary progressive multiple sclerosis, Alzheimer’s disease, and ALS.

The stock has surged in 2025, primarily due to significant progress in clinical development and strategic updates. The most notable catalyst was the announcement that Tiziana would begin a Phase 2 clinical trial of intranasal Foralumab for mild Alzheimer’s disease in the first half of 2025, following successful IND submissions and expanded access programs for both Alzheimer’s and non-active secondary progressive multiple sclerosis.

In December 2024, the company began dosing patients with moderate Alzheimer’s under an expanded access program, which further fueled investor optimism. Additionally, Tiziana received a grant from the ALS Association to support a Phase 2 clinical trial in ALS.

TLSA stock is up 95.35% year-to-date.

Page 3 of 14